Biogen Inc Total Assets
Biogen Inc total assets. Based on the latest financial reports, Biogen Inc (BIIB) holds total assets worth $32.09 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BIIB stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Biogen Inc (1985–2025)
Total assets of Biogen Inc from 1985 to 2025. This chart illustrates how Biogen Inc's total assets have evolved over time, based on quarterly financial data. See BIIB stock price and chart for real-time trading data and today's change.
Biogen Inc - Asset Composition Analysis
Biogen Inc Total Assets Breakdown (December 2025)
Biogen Inc total assets breakdown as of December 2025. Biogen Inc's total assets of $32.09 Billion consist of 30.5% current assets and 69.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.2% |
| Accounts Receivable | $1.87 Billion | 6.3% |
| Inventory | $2.17 Billion | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.18 Billion | 31.2% |
| Goodwill | $6.49 Billion | 22.1% |
Asset Composition Trend (1985–2025)
This chart illustrates how Biogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Biogen Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biogen Inc's current assets represent 30.5% of total assets in 2025, a decrease from 66.4% in 1985.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2025, down from 62.4% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 2.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 31.2% of total assets.
Biogen Inc Competitors by Total Assets
Key competitors of Biogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
Biogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.50 | 1.70 |
| Quick Ratio | 1.26 | 1.79 | 1.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.39 Billion | $4.78 Billion | $2.95 Billion |
Biogen Inc - Advanced Valuation Insights
This section examines the relationship between Biogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | $29.44 Billion |
| Market Capitalization | $32.27 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Biogen Inc's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Biogen Inc's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biogen Inc (1985–2025)
The table below shows the annual total assets of Biogen Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $29.44 Billion | +4.96% |
| 2024-12-31 | $28.05 Billion | +4.49% |
| 2023-12-31 | $26.84 Billion | +9.33% |
| 2022-12-31 | $24.55 Billion | +2.83% |
| 2021-12-31 | $23.88 Billion | -3.01% |
| 2020-12-31 | $24.62 Billion | -9.60% |
| 2019-12-31 | $27.23 Billion | +7.69% |
| 2018-12-31 | $25.29 Billion | +6.92% |
| 2017-12-31 | $23.65 Billion | +3.39% |
| 2016-12-31 | $22.88 Billion | +17.29% |
| 2015-12-31 | $19.50 Billion | +36.24% |
| 2014-12-31 | $14.32 Billion | +20.68% |
| 2013-12-31 | $11.86 Billion | +17.11% |
| 2012-12-31 | $10.13 Billion | +11.94% |
| 2011-12-31 | $9.05 Billion | +11.83% |
| 2010-12-31 | $8.09 Billion | -5.37% |
| 2009-12-31 | $8.55 Billion | +0.86% |
| 2008-12-31 | $8.48 Billion | -1.74% |
| 2007-12-31 | $8.63 Billion | +0.89% |
| 2006-12-31 | $8.55 Billion | +2.22% |
| 2005-12-31 | $8.37 Billion | -8.72% |
| 2004-12-31 | $9.17 Billion | -3.56% |
| 2003-12-31 | $9.50 Billion | +373.54% |
| 2002-12-31 | $2.01 Billion | +16.61% |
| 2001-12-31 | $1.72 Billion | +20.20% |
| 2000-12-31 | $1.43 Billion | +12.04% |
| 1999-12-31 | $1.28 Billion | +38.20% |
| 1998-12-31 | $924.72 Million | +13.63% |
| 1997-12-31 | $813.83 Million | +28.25% |
| 1996-12-31 | $634.57 Million | +35.25% |
| 1995-12-31 | $469.20 Million | +24.17% |
| 1994-12-31 | $377.86 Million | +5.84% |
| 1993-12-31 | $357.00 Million | +14.72% |
| 1992-12-31 | $311.20 Million | +22.96% |
| 1991-12-31 | $253.10 Million | +59.68% |
| 1990-12-31 | $158.50 Million | +9.16% |
| 1989-12-31 | $145.20 Million | +79.48% |
| 1988-12-31 | $80.90 Million | +0.25% |
| 1987-12-31 | $80.70 Million | -20.02% |
| 1986-12-31 | $100.90 Million | +17.60% |
| 1985-12-31 | $85.80 Million | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more